In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations
- 1 July 2004
- journal article
- Published by Elsevier BV in Clinical Microbiology & Infection
- Vol. 10 (7), 662-665
- https://doi.org/10.1111/j.1469-0691.2004.00917.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Characterization of rifampicin-resistant Mycobacterium tuberculosis in TaiwanJournal of Medical Microbiology, 2003
- Characterization of rpoB Mutations in Rifampin-Resistant Clinical Isolates of Mycobacterium tuberculosis from Turkey by DNA Sequencing and Line Probe AssayJournal of Clinical Microbiology, 2002
- Molecular genetic basis of antimicrobial agent resistance inMycobacterium tuberculosis: 1998 updateTubercle and Lung Disease, 1998
- Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 1998
- Contribution of rpoB Mutations to Development of Rifamycin Cross-Resistance in Mycobacterium tuberculosisAntimicrobial Agents and Chemotherapy, 1998
- Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosisJournal of Antimicrobial Chemotherapy, 1995
- Detection of rifampicin-resistance mutations in Mycobacterium tuberculosisThe Lancet, 1993
- Multidrug-resistant TuberculosisAnnals of Internal Medicine, 1992
- In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteriaTubercle, 1987
- Permeability Barrier to Rifampin in MycobacteriaAntimicrobial Agents and Chemotherapy, 1977